Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSe Trial

Affiliation auteurs!!!! Error affiliation !!!!
TitreVemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSe Trial
Type de publicationJournal Article
Year of Publication2018
AuteursMazieres J., Montane L., Barlesi F., Coudert B., Souquet P.J, Otto J., Gervais R., Moro-Sibilot D., Monnet I., Brain E., Huillard O., Quere G., Debieuvre D., Fabre E., Jaffro M., Collot S., Ferretti G., Tiffon C., C. Oukhatar M-A, Blay J.
JournalJOURNAL OF THORACIC ONCOLOGY
Volume13
PaginationS348-S349
Date PublishedOCT
Type of ArticleMeeting Abstract
ISSN1556-0864
Mots-clésBRAF mutation, NSCLC, vemurafenib
DOI10.1016/j.jtho.2018.08.302